<DOC>
	<DOCNO>NCT02713867</DOCNO>
	<brief_summary>The primary objective study show PFS ( progress-free survival ) rate 6 month 1 year randomization , Nivolumab 480 mg every 4 week non-inferior nivolumab 240 mg every 2 week subject advanced/metastatic ( Stage IIIb/IV ) NSCLC ( non-Sq Sq ) .</brief_summary>
	<brief_title>A Dose Frequency Optimization , Trial Nivolumab 240 mg Every 2 Weeks v Nivolumab 480 mg Every 4 Weeks Subjects With Advanced Metastatic Non-small Cell Lung Cancer Who Received Up 12 Months Nivolumab 3 mg/kg 240 mg Every 2 Weeks</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Histologically cytologically document Squamous nonSquamous Nonsmall cell lung cancer ( NSCLC ) ( Stage IIIB/IV ) , recurrent progressive disease follow multimodal therapy Patients must receive prestudy nivolumab 12 month 2 consecutive tumor assessment confirm Complete response ( CR ) , Partial response ( PR ) , Stable disease ( SD ) Measurable disease start prestudy nivolumab treatment Eastern Cooperative Oncology Group ( ECOG ) Performance status ( PS ) 02 Carcinomatous meningitis Untreated , symptomatic Central nervous system ( CNS ) metastases Symptomatic interstitial lung disease Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>